Teva/Actavis Generics company information, Employees & Contact Information

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy Yahoo Finance

Teva Pharmaceuticals Announces FDA Approval and Launch of First Generic GLP-1 for Weight Loss, Saxenda® (Liraglutide Injection) Quiver Quantitative

Global Pharma Giant Teva Pharmaceutical Schedules Q3 2025 Financial Results Call for November 5 Stock Titan

Teva Releases Q3 2025 Aide Memoire Macau Business

Global Healthcare Conference Season: Teva CEO to Present Company Strategy at Morgan Stanley & BofA Events Stock Titan

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease Yahoo Finance

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 GlobeNewswire

Teva Pharmaceuticals Engages Honeywell to Help Reduce Building Energy Use and Carbon Impact Honeywell

Teva Earnings: Q2 2025 Results Release at 7 AM, Conference Call at 8 AM ET July 30 Stock Titan

Teva Pharmaceutical Industries Ltd. to Announce Second Quarter 2025 Financial Results on July 30, 2025 Quiver Quantitative

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia Yahoo Finance

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 Yahoo Finance

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City GlobeNewswire

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA Yahoo Finance

Teva Pharmaceutical Industries Ltd. to Present Phase 3 SOLARIS Trial Data at 2025 Psych Congress Annual Meeting Quiver Quantitative

Teva Pharmaceutical Industries Ltd. CEO Richard Francis to Present at Upcoming Investor Conferences in September 2025 | TEVA Stock News Quiver Quantitative

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe Sahm

Teva's Crucial Phase 3 SOLARIS Trial Results for Olanzapine LAI Coming at Major Psych Congress Meeting Stock Titan

Presence of Particulate Prompts Recall of Topotecan Injection Medical Professionals Reference

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024 The AI Journal

Teva's Breakthrough Cancer Immunotherapy Gains Momentum with Major Asian Market Partnership Stock Titan

Disappointing Results for Deutetrabenazine in Tourette Syndrome Trials Medical Professionals Reference

Idarubicin Hydrochloride Injection Recalled Due to Presence of Particulate in Vial Medical Professionals Reference

ArmonAir Digihaler Approved for Asthma Maintenance Treatment Medical Professionals Reference

Top five generic drug makers European Pharmaceutical Review

Teva Announces New Brand Positioning and Visual Identity in North America PRWeb

Ajovy Now Available in Autoinjector Device for Migraine Prevention Medical Professionals Reference

FDA Approves Prefilled Autoinjector Device for Ajovy Medical Professionals Reference

Two blood pressure drugs recalled for potential cancer risk The Columbus Dispatch

Granix Indication Expanded to Include Pediatric Patients Medical Professionals Reference

Generic Minastrin 24 Fe Available Medical Professionals Reference

Platelet-Reducing Agent Available Again Medical Professionals Reference

Teva Pharmaceutical Industries Ltd Via Ritzau

FDA: Blood Pressure Medicine Recalled Due To Chemical Linked In Cancer CBS News

QNASL Approved for Seasonal and Perennial Allergic Rhinitis Medical Professionals Reference

Teva Pharmaceutical Investor Conference Call At 8:30 AM ET RTTNews

Teva To Present At Barclays Capital Conference; Webcast At 4:15 PM ET RTTNews